{"id":"W4406633419","doi":"10.1016/j.vaccine.2024.126628","title":"Corrigendum to “A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)” [Vaccine 41 (2023) 3387–3398]","year":2025,"lang":"en","type":"erratum","venue":"Vaccine","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Merck","keywords":"Tolerability; Immunogenicity; Medicine; Multicenter study; Double blind; Randomized controlled trial; Adverse effect; Pharmacology; Internal medicine; Immunology; Antibody; Alternative medicine; Pathology; Placebo","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005370576,0.002383264,0.003349849,0.001680721,0.00167542,0.002218458,0.002923101,0.006361771,0.08151342],"category_scores_gemma":[0.03115285,0.001213832,0.002607315,0.001205812,0.001095564,0.001092729,0.0009811238,0.007026192,0.03308428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00341243,"about_ca_system_score_gemma":0.00507475,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0185454,"about_ca_topic_score_gemma":0.03375714,"domain_scores_codex":[0.9967111,0.001029546,0.0004592581,0.0003446621,0.001163221,0.0002921444],"domain_scores_gemma":[0.9838568,0.005632719,0.001122231,0.0006208264,0.007575113,0.001192448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001436812,0.00002831982,0.00003164708,0.0001660927,0.00002872615,0.00007446209,0.000003817233,0.00002535737,0.00004407452,0.0001226129,0.9939872,0.005344009],"study_design_scores_gemma":[0.001115134,0.0002058632,0.001528085,0.0005368155,0.0002134989,0.0002184579,0.0000197703,0.0002757524,0.0004151614,0.0006153789,0.99481,0.00004616414],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0001762144,0.005084235,0.0005728152,0.08210424,0.9031193,0.0002421119,0.001832674,0.0002549366,0.006613492],"genre_scores_gemma":[0.004946615,0.01150977,0.003163781,0.275059,0.4753998,0.000839931,0.004482572,0.0004074195,0.2241911],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.08151342,"threshold_uncertainty_score":0.2726896,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07786025133826414,"score_gpt":0.418630992328775,"score_spread":0.3407707409905109,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}